|
Jul 24
|
Cytokinetics to Announce Second Quarter Results On August 7, 2025
|
|
Jul 6
|
Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT
|
|
Jun 5
|
Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound?
|
|
May 18
|
Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress
|
|
Apr 22
|
Cytokinetics to Announce First Quarter Results on May 6, 2025
|
|
Apr 22
|
Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)
|
|
Mar 5
|
Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK)
|
|
Mar 3
|
Cytokinetics to Participate in March Investor Conferences
|
|
Mar 1
|
Cytokinetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Feb 20
|
Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now
|
|
Feb 20
|
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Feb 19
|
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Feb 13
|
Cytokinetics to Announce Fourth Quarter Results on February 27, 2025
|
|
Feb 11
|
Cytokinetics Names Robert E. Landry to Board of Directors
|
|
Jan 3
|
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
|